2023
Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder
Kiluk B, Kleykamp B, Comer S, Griffiths R, Huhn A, Johnson M, Kampman K, Pravetoni M, Preston K, Vandrey R, Bergeria C, Bogenschutz M, Brown R, Dunn K, Dworkin R, Finan P, Hendricks P, Houtsmuller E, Kosten T, Lee D, Levin F, McRae-Clark A, Raison C, Rasmussen K, Turk D, Weiss R, Strain E. Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder. JAMA Psychiatry 2023, 80: 84-92. PMID: 36449315, PMCID: PMC10297827, DOI: 10.1001/jamapsychiatry.2022.4020.Peer-Reviewed Original ResearchConceptsOpioid use disorderOUD treatmentUse disordersClinical trial design challengesAddiction Clinical Trial TranslationsΜ-opioid receptor systemNetworks (ACTTION) public-private partnershipTrial design challengesOngoing opioid epidemicTrial design considerationsClinical trial design considerationsRole of treatmentQuality of lifeAntagonist medicationsEmerging TreatmentsAdverse eventsOpioid usePrimary outcomeStages of treatmentPatient preferencesMOR agonistsOpioid epidemicConsensus recommendationsCurrent evidenceTreatment retention
2020
Evaluating a Longitudinal Mediation Model of Perceived Stress, Depressive Symptoms, and Substance Use Treatment Outcomes
Roos CR, Kiluk BD, McHugh RK, Carroll KM. Evaluating a Longitudinal Mediation Model of Perceived Stress, Depressive Symptoms, and Substance Use Treatment Outcomes. Psychology Of Addictive Behaviors 2020, 34: 660-668. PMID: 32297754, PMCID: PMC7483283, DOI: 10.1037/adb0000581.Peer-Reviewed Original ResearchConceptsIllicit opioid useOpioid useDepressive symptomsUse disordersSubstance use outcomesMethadone treatmentStandard methadone treatmentTrial of galantamineUse outcomesOpioid use disorderSubstance Use Treatment OutcomesSubstance use disordersCocaine use disorderCognitive behavioral therapyLongitudinal treatment studyTreatment outcomesPredictors of endPosttreatment outcomesSymptomsTreatment studiesSignificant total effectSubstance useBaselineOutcomesDisorders
2019
Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder
Kiluk BD, Yip SW, DeVito EE, Carroll KM, Sofuoglu M. Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder. Clinical Psychological Science 2019, 7: 1190-1206. PMID: 32042509, PMCID: PMC7009780, DOI: 10.1177/2167702619855659.Peer-Reviewed Original ResearchOpioid use disorderClinical featuresUse disordersHigher anhedonia scoresKey clinical featuresRate of participantsAnhedonia scoresOpioid-dependent sampleOpioid cravingOpioid useTreatment adherenceHealthy controlsSignificant anhedoniaPharmacological interventionsAssessment of anhedoniaMajority of studiesPotential targetAnhedoniaTreatmentTime courseDisordersSignificant knowledge gapsScoresPotential implicationsCritical need
2018
Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder
Carroll KM, Nich C, Frankforter TL, Yip SW, Kiluk BD, DeVito EE, Sofuoglu M. Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. Drug And Alcohol Dependence 2018, 192: 264-270. PMID: 30300800, PMCID: PMC6203294, DOI: 10.1016/j.drugalcdep.2018.08.019.Peer-Reviewed Original ResearchConceptsOpioid use disorderOral naltrexoneUse disordersAffective symptomsVoucher-based contingency managementDysphoric symptomsAffective distressOral naltrexone treatmentMultiple baseline characteristicsBaseline characteristicsNaltrexone treatmentHigh riskNaltrexoneSomatic symptomsSymptomsContingency managementTreatmentHigh rateDistressSubstantial evidenceTrialsTheoretical benefitsDisordersAffective discomfortParticipants